135O - A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session New approaches in rare thoracic tumors
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Lung and other Thoracic Tumours
Presenter Benjamin Besse
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors B. Besse1, F. Barlesi2, I. Demedts3, J. Fuentes Pradera4, A. Renault5, G. Robinet6, B. Frimodt-Moller7, M. Gil8, J. Vansteenkiste9
  • 1Dept Of Cancer Medicine, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 2Aix-Marseille University - Faculté de Médecine Nord, Marseille/FR
  • 3AZ Delta, Roeselare/BE
  • 4Oncology, Hospital Universitario Nuestra Senora de Valme, Sevilla/ES
  • 5Centre Hospitalier de Pau, Pau/FR
  • 6C.H.U. Brest - Hôpital Morvan, Brest/FR
  • 7Eli Lilly Denmark, Copenhagen/DK
  • 8Eli Lilly Polska, Warsaw/PL
  • 9University Hospital KU Leuven, Leuven/BE


Necitumumab and abemaciclib inhibit tumor progression by different, independent mechanisms, and both have shown activity in patients with non-small cell lung cancer (NSCLC).